Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (12)	10/30/1998 1:48:00 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1386

Ariella, Beautifully said. I agree with most everything that you've said. But, I still believe that PARS can do better in presenting their case to the investment community without a large drain on personnel and without a lot of hype. To my mind a glaring case in point is the LE-T Phase II trial. The completion of a Phase II trial and its results are a major event for a small company. Why hasn't PARS said anything? Why has there not been a press release indicating the completion of this trial and its results? Silence about an event like this is normally taken as indicating a poor outcome. I don't believe that that is the case. Rather it is a continuation of PARS lack of communication with the investment community. I don't mean investors who make the effort to call them. From what I hear they are very forthcoming with them. As a matter of fact, from what I've heard, they are actually too forthcoming. Things should not be told to people who call that is not already public information. The problem I have is with PARS communication with the community as a whole who might not be very familiar with PARS. I guarantee that the stock price would be higher while maintaining credibility if they'd simply communicate more often about their accomplishments. John de C

To: Ariella who wrote (12)	11/2/1998 7:02:00 AM
From: Gabe Fernandez	Read Replies (1) \| Respond to of 1386

Ariella: Great presentation of Pharmos past, present and future. It is very difficult to be able to understand very well the medical aspects of Pharmo's products present and those like HU-211 and Tamoxifen analogs,and the great prospects for success in the medical field. You cannot help to wonder the why's of the short attacks and the low price of this issue. I certainly hope your analysis is correct. Good luck to you and please continue your valuable information to this thread. gabe or gfdz1@aol.com